Observational studyBlood advances2022
Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study.
Observational study in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01303900 (Cardiovascular Disease in Adult Haemophilia Patients), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cardiovascular Disease in Adult Haemophilia Patients
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Cardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort.Blood advances · 2026Article
- Ageing with Haemophilia: Comorbidities in Focus.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- The aging hemophilia patient.Hematology. American Society of Hematology. Education Program · 2025Review
- Normalization in hemophilia: conceptual foundations and clinical implications.Research and practice in thrombosis and haemostasis · 2025Review
- Burden of Haemophilia A in South Korea: A Serial Cross-Sectional Study From 2008 to 2021.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Article
- Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy.European heart journal. Cardiovascular pharmacotherapy · 2025Review
- Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries-Comparisons to Matched Controls.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Observational
- Coronary artery stenosis in Japanese people living with HIV-1 with or without haemophilia.Global health & medicine · 2024Article
- Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.Research and practice in thrombosis and haemostasis · 2024Article
- Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance.HemaSphere · 2023Article
- Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review.Research and practice in thrombosis and haemostasis · 2023Article
- Cardiovascular Risk Scores among Asymptomatic Adults with Haemophilia.Arquivos brasileiros de cardiologia · 2023Article
- Gene therapy - are we ready now?Haemophilia : the official journal of the World Federation of Hemophilia · 2022Article
- Cardiovascular disease in hereditary haemophilia: The challenges of longevity.British journal of haematology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophilia is a congenital bleeding disorder caused by low levels of clotting factor VIII or IX. The life expectancy of people with hemophilia (PWH) has increased with the availability of clotting factor concentrates. At the same time, the incidence of cardiovascular disease (CVD) has increased; in retrospective studies, there are conflicting data regarding if, despite this increase, the incidence is still lower than in the general population. We prospectively compared the incidence of CVD in PWH vs the predicted incidence. This prospective, multicenter, observational study included adult PWH (aged >30 years) from The Netherlands and United Kingdom. They were followed up for a 5-year period, and CVD incidence was compared with a predicted event rate based on the QRISK2-2011 CVD risk model. The primary end point was the observed fatal and nonfatal CVD incidence after 5 years compared with the estimated events and in relation to severity of hemophilia. The study included 709 patients, of whom 687 (96.9%) completed 5 years' follow-up or reached an end point. For 108 patients, the QRISK score could not be calculated at inclusion. For the remaining 579, fewer CVD events were observed than predicted: 9 vs 24 (relative risk, 0.38; 95% confidence interval, 0.18-0.80; P = .01), corresponding with an absolute risk reduction of 2.4%. Severe hemophilia treated on demand had the highest risk reduction. There was no statistically significant relation between severity of hemophilia and incidence of CVD. In hemophilia, a lower-than-predicted CVD incidence was found, supporting the theory that hemophilia protects against CVD. The study is registered at www.clinicaltrials.gov as #NCT01303900.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.